Pharsight

Vimpat generic

Vimpat is a drug developed and owned by Ucb Inc. It leverages the active ingredient, lacosamide, and was first authorized for market use on 28 October, 2008. The drug has a total of 1 patent, with 1 of them already expired. The drug is available in solution and intravenous dosage forms.

When will Vimpat generic be available?

Vimpat generics are likely to be available after 28 April, 2026. Although the patent USRE38551 has already expired, the last remaining patent protects it from generic drug development until then.

Vimpat uses

Vimpat is primarily used for the treatment of partial-onset seizures in patients who are 4 years old and older. It is also used as an initial loading dose for monotherapy or adjunctive therapy in treating partial onset seizures in epileptic patients aged 17 years or older. Vimpat's active ingredient, lacosamide, works effectively to control seizures.

Vimpat patent expiration

Vimpat is protected by one final patent that expires on 28 April, 2026, delaying the possible advent of Vimpat generic until then. Below is the details of the patent:

Litigations filed on Vimpat

Vimpat dosage

Want to ask something?